Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MMP15 | P51511 | 1/20 | 0.43 |
| ▸ | MMP16 | P51512 | 1/20 | 0.43 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3679509 | 1.00 | MMP2 (0.43) | MMP2MMP9MMP12MMP14MMP15 | |
| Trifluoroacetic Acid SCHEMBL3679506 | 0.94 | MMP2 (0.44) | MMP2MMP9MMP12MMP14MMP15 | |
| SCHEMBL13409972 | 0.91 | MMP2 (0.50) | MMP2MMP9MMP12MMP14MMP15 | |
| SCHEMBL3687172 | 0.87 | CRAT (0.49) | MMP2MMP9MMP12MMP14MMP15 | |
| SCHEMBL3687169 | 0.87 | CRAT (0.49) | MMP2MMP9MMP12MMP14MMP15 | |
| SCHEMBL3679511 | 0.83 | CTSG (0.42) | — | |
| SCHEMBL13409957 | 0.81 | ACACB (0.47) | MMP2MMP9MMP12MMP14MMP15 | |
| Trifluoroacetic Acid SCHEMBL3690941 | 0.79 | PPARG (0.52) | MMP9 | |
| Trifluoroacetic Acid SCHEMBL3690945 | 0.79 | PPARG (0.52) | MMP9 | |
| SCHEMBL14069885 | 0.78 | NPC1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | MMP2 961/4885MMP9 1084/4885MMP12 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.